Exact claim · Version 1 · Reviewed
“Phase 3 trials showed retatrutide produced average weight reduction above 20%.”
A verdict on this wording and scope, not a universal grade for Retatrutide.
01 · Verdict
Supported with scope
Lilly reported average weight reduction of up to 20.8% in TRIUMPH-2 and up to 22.6% in TRIUMPH-3 at 80 weeks. These are sponsor-reported topline efficacy-estimand figures and group averages, not individual outcomes, and no full peer-reviewed report of either trial was available in the records reviewed here.
- Evidence basis
- Sponsor-reported trial results
- Scope
- Adults meeting the TRIUMPH-2 (obesity or overweight with type 2 diabetes) and TRIUMPH-3 (severe obesity with established cardiovascular disease) entry criteria at 80 weeks, as disclosed by Lilly in July 2026.
- Category
- Clinical outcomes
02 · Primary record
Check the attached evidence
01TRIUMPH-2 and TRIUMPH-3 topline resultsEli Lilly and Company · Reference · 2026
Supports the scoped claim02TRIUMPH-2 phase 3 study recordClinicalTrials.gov · Trial registry · 2026
Supports the scoped claim03TRIUMPH-3 phase 3 study recordClinicalTrials.gov · Trial registry · 2026
Supports the scoped claim
Supports the scoped claim02TRIUMPH-2 phase 3 study recordClinicalTrials.gov · Trial registry · 2026
Supports the scoped claim03TRIUMPH-3 phase 3 study recordClinicalTrials.gov · Trial registry · 2026
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.